WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update. “As we enter 2024, we are financially strong, focused and motivated,” stated Dr. Neal Walker, co-founder and Interim Chief Executive Officer & President of Aclaris. “Returnin
Neal-walker
Sun-pharma
Eli-lilly
Pediatrix-therapeutics-inc
Nasdaq
Washington-university
Exchange-commission
Aclaris-therapeutics-inc
Sun-pharmaceutical-industries-inc
Washington-university-in-st
Interim-chief-executive-officer
Development-highlights